NSCLC Clinical Trial Landscape

The NSCLC clinical trial landscape in 2026

Non-small cell lung cancer remains the most trial-active solid tumor type globally. With 389 actively recruiting studies and 116 Phase 3 programs, NSCLC in 2026 is defined by three strategic battles simultaneously: the TROP2 ADC race between Merck and AstraZeneca, the post-osimertinib resistance setting where multiple mechanisms are being tested in combination, and the expansion of KRAS G12C inhibition beyond sotorasib into next-generation inhibitors with checkpoint combinations.

The approved standard of care established the framework: pembrolizumab + chemotherapy or osimertinib (EGFR-mutated). But each approved therapy created a resistance population — patients who progress on pembrolizumab or who exhaust osimertinib — that now defines the Phase 3 opportunity. Both Merck and AstraZeneca are targeting these populations aggressively with TROP2-directed ADCs (sacituzumab tirumotecan/MK-2870 and datopotamab deruxtecan/DATO-DXd respectively), each having launched 3–4 simultaneous Phase 3 trials across patient subgroups.

The 2026 NSCLC Phase 3 class spans TROP2 ADCs, EGFR×HER3 bispecific ADCs, next-generation KRAS G12C inhibitors with checkpoint combinations, CTLA-4/PD-1 bispecifics, and the first mRNA cancer vaccine Phase 3 in NSCLC (V940/intismeran autogene). NSCLC is simultaneously the most competitive CI space and the most important for identifying the next generation of lung cancer standards.

• TROP2-directed ADCs — MK-2870/sacituzumab tirumotecan (Merck, 4 Phase 3 trials), DATO-DXd/datopotamab deruxtecan (AstraZeneca, 3 Phase 3 trials) — targeting post-TKI EGFR-mutated NSCLC and checkpoint-refractory patients
• EGFR/HER3 ADC combinations — telisotuzumab adizutecan (AbbVie) + osimertinib Phase 3 in EGFR-mutated NSCLC; HER3-DXd (patritumab deruxtecan, AstraZeneca) in EGFR post-TKI
• Next-generation KRAS G12C — calderasib (MK-1084, Merck) entering Phase 3 in combination with pembrolizumab; adagrasib + pembrolizumab Phase 3 combinations
• CTLA-4/PD-1 bispecifics — volrustomig (MEDI5752, AstraZeneca) in combination and sequential strategies
• mRNA cancer vaccines — V940/intismeran autogene (Merck/Moderna) + pembrolizumab vs placebo + pembrolizumab Phase 3 (NCT06077760)
• Osimertinib combination/extension — AstraZeneca extending adjuvant osimertinib into Stage IA2/IA3 NSCLC (earlier-stage program)
• KRAS G12D, SOS1 inhibitors, and other emerging targets entering Phase 1/2

Key Phase 3 NSCLC trials (2026)

Selected Phase 3 programs with the highest BD, CI, and investment relevance:

The TROP2 ADC race — Merck vs AstraZeneca, 7 Phase 3 trials

The most commercially consequential competitive intelligence story in NSCLC right now is the TROP2 ADC race between Merck's sacituzumab tirumotecan (MK-2870) and AstraZeneca/Daiichi's datopotamab deruxtecan (DATO-DXd). Both drugs target TROP2, a cell surface antigen overexpressed in lung cancer. TROP2 ADCs use the antibody to deliver cytotoxic payloads (topoisomerase inhibitors in both cases) preferentially to tumor cells.

Merck's MK-2870 (sacituzumab tirumotecan) — 4 simultaneous Phase 3 trials

Sacituzumab tirumotecan (formerly SN38-bearing, now a TOP1 inhibitor payload) is Merck's lead TROP2 ADC in NSCLC. Merck has launched four simultaneous Phase 3 programs, covering the major NSCLC segments:

• MK-2870-004 — TROP2 ADC vs chemotherapy in EGFR-mutated NSCLC patients who progressed on a prior EGFR TKI (post-osimertinib resistance). This is the largest post-TKI NSCLC opportunity.
• MK-2870-007 — TROP2 ADC + pembrolizumab vs pembrolizumab alone in PD-L1 TPS ≥50% first-line metastatic NSCLC without actionable mutations. Direct challenge to pembrolizumab monotherapy as the standard of care in this setting.
• MK-2870-009 — TROP2 ADC vs pemetrexed/carboplatin in EGFR-mutated post-TKI NSCLC. A second trial in the same post-TKI setting with different control arm.
• MK-2870-023 — Pembrolizumab with or without TROP2 ADC maintenance in squamous NSCLC. Addressing the squamous subtype where no post-checkpoint options exist.

AstraZeneca's DATO-DXd (datopotamab deruxtecan) — 3 simultaneous Phase 3 trials

DATO-DXd is AstraZeneca's TROP2 ADC from the Daiichi Sankyo partnership (same DXd payload technology as T-DXd). AstraZeneca has a strategic advantage: they can combine DATO-DXd with their own osimertinib and rilvegostomig (PD-1/TIGIT bispecific) assets:

• NCT07291037 — DATO-DXd vs docetaxel in TROP2-positive previously treated non-squamous NSCLC. Targeting the chemotherapy-era 2L setting.
• NCT06417814 — DATO-DXd ± osimertinib vs platinum doublet chemotherapy in EGFR-mutated NSCLC. A combination trial leveraging AstraZeneca's EGFR franchise.
• NCT06357533 — DATO-DXd + rilvegostomig vs pembrolizumab or SOC in first-line PD-L1-high non-squamous NSCLC. The TIGIT combination angle — adding PD-1/TIGIT dual blockade to TROP2 ADC.

For CI teams, the TROP2 ADC story creates an interconnected web of trials to monitor: any interim readout from MK-2870-004 will affect AstraZeneca's DATO-DXd enrollment strategy and investor expectations, and vice versa. New Phase 2 TROP2 ADC registrations in NSCLC from emerging biotechs (third-wave TROP2 ADCs with novel payloads or antibodies) are high-value early signals — the player that gets approved first in a specific NSCLC subtype gains a durable advantage.

Osimertinib: from LAURA to adjuvant extension

Osimertinib (Tagrisso) defines the EGFR-mutated NSCLC standard. The LAURA trial established osimertinib as adjuvant consolidation after definitive chemoradiotherapy in unresectable Stage III EGFR-mutated NSCLC — FDA approved based on dramatic PFS improvement. AstraZeneca is now extending the adjuvant osimertinib indication further: NCT05120349 tests osimertinib in even earlier-stage disease (IA2–IA3) following complete resection, potentially capturing NSCLC patients before metastatic recurrence.

The osimertinib adjuvant expansion creates a downstream CI signal: as osimertinib penetrates into earlier disease stages, the pool of osimertinib-resistant metastatic NSCLC patients (the target for DATO-DXd, MK-2870-004, telisotuzumab adizutecan) grows — all four TROP2/HER3 ADC post-TKI trials are partly tracking osimertinib market expansion as a leading indicator of their addressable patient population.

KRAS G12C next generation — calderasib and combination trials

Sotorasib (Lumakras) and adagrasib (Krazati) established KRAS G12C inhibition in NSCLC, but response durability is limited by acquired resistance (most commonly via secondary KRAS mutations, RTK bypass, or downstream RAS/MAPK reactivation). The second generation of KRAS G12C inhibitors is designed to overcome resistance and achieve deeper responses in combination with checkpoint inhibitors:

• Calderasib (MK-1084) — Merck's next-generation KRAS G12C inhibitor designed to bind KRAS G12C with improved potency and to address acquired resistance mutations. KANDLELIT-004 (NCT06345729) tests calderasib + pembrolizumab in KRAS G12C PD-L1 ≥50% NSCLC — the combination hypothesis being that KRAS G12C inhibition increases immunogenicity and synergizes with PD-1 checkpoint blockade.
• Multiple adagrasib combination Phase 3 trials are running across NSCLC subgroups.
• Multiple KRAS G12D inhibitors entering Phase 1/2 — watching for NSCLC expansion of KRAS G12D programs is a 12-24 month forward signal.

mRNA cancer vaccines enter NSCLC Phase 3

V940 (intismeran autogene) is Merck and Moderna's personalized mRNA cancer vaccine (same platform as mRNA-4157). The NSCLC Phase 3 (NCT06077760) tests V940 + pembrolizumab versus placebo + pembrolizumab. V940 is individualized — each patient's tumor is sequenced, neoantigens are identified, and a personalized mRNA vaccine is synthesized encoding up to 34 patient-specific neoantigens. The vaccine aims to prime neoantigen-specific T cells that then kill tumor cells; checkpoint blockade amplifies and sustains that T cell response.

The NSCLC readout will be among the most-watched oncology binary events of 2027 — validating or disconfirming the personalized mRNA cancer vaccine thesis at scale. A positive result would have broad implications beyond NSCLC and trigger partnering/licensing activity across the therapeutic vaccine space.

What we monitor for NSCLC

Our pipeline pulls from ClinicalTrials.gov every day. For an NSCLC watch profile, alerts can be configured for:

• Conditions: non-small cell lung cancer, NSCLC, lung adenocarcinoma, squamous cell lung, stage III/IV NSCLC
• Molecular targets: EGFR mutation, KRAS G12C, KRAS G12D, ALK fusion, ROS1 fusion, RET fusion, MET exon 14, HER2, TROP2, HER3, PD-L1
• Key agents: sacituzumab tirumotecan (MK-2870), datopotamab deruxtecan (DATO-DXd), calderasib, adagrasib, sotorasib, osimertinib, pembrolizumab, nivolumab, telisotuzumab adizutecan, rilvegostomig, volrustomig
• Phase filters: Phase 1 (novel mechanisms), Phase 3 (registration programs)
• Sponsor type: large pharma (Merck/MSD, AstraZeneca, BMS, Roche, AbbVie), emerging biotech, academic cooperative groups

Who uses NSCLC trial monitoring

• Pharma BD and licensing teams — tracking TROP2 ADC, KRAS G12C, and ADC combination programs entering Phase 1/2 as co-development targets; monitoring calderasib and DATO-DXd enrollment pace as competitive signals
• Oncology investors and fund analysts — MK-2870-004 and DATO-DXd interim data catalysts as AstraZeneca and Merck binary events; V940 mRNA vaccine Phase 3 as Moderna/Merck catalyst
• Lung cancer CROs — identifying new sponsor relationships across complex TKI-combination and TROP2 ADC trial designs; monitoring site networks for post-TKI NSCLC patient recruitment
• Medical affairs at TKI and checkpoint sponsors — watching DATO-DXd and MK-2870 combinations as competitive threats to osimertinib and pembrolizumab franchises post-progression
• Patient advocacy and clinical teams — identifying recruiting trials for KRAS G12C, post-osimertinib, or PD-L1-high NSCLC patients seeking options after approved therapy failure

Frequently asked questions